The market barely flinched on Humana’s earnings, with the stock up just 0.3% around US$366. That muted move sits against a report defined by margin repair rather than headline growth. Quarterly basic earnings per share of US$5.78 and net income of US$694m came alongside a clear message. Management is leaning hard into restoring Medicare Advantage profitability after a year of thinner margins and a large one off loss in the trailing period.

For investors, the real story is whether this slow price reaction catches up to the scale of the margin rebuilding plan now in motion. The detailed numbers tell that story.

Is Humana a deep value opportunity or simply expensive on the wrong metrics? Compare the discounted cash flow gap with its current P/E and peer multiples on our valuation analysis for Humana

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): US$40,867m vs. US$32,388m (up about 26%)
• Net Income (Excl. Extra Items, Q2 2026 vs Q2 2025): US$694m vs. US$545m (up about 27%)
• Basic EPS (Q2 2026 vs Q2 2025): US$5.78 vs. US$4.52 (up about 28%)
• Trailing Twelve Month Net Profit Margin (FY 2026 vs Prior Year): 0.9% vs. 1.3% (margin lower year on year)

Prefer visual charts instead of scrolling through pages of earnings tables and margin figures? See Humana’s full financial picture, including a clear view of its profitability and margins trend, in the interactive company report for Humana.

Evaluating Humana’s Margin Repair Bull Case

Bulls argue that Humana can restore Medicare Advantage profitability through better cost control, higher quality scores and tighter operations. The latest quarter gives concrete proof points rather than just promises. Revenue of US$40,867m and net income of US$694m come with a materially lower operating cost ratio, down 120 basis points year on year, and management expects about a 150 basis point cut for 2026. That supports the claim that operating model changes are starting to work.

The thesis also leans on value based care and Stars recovery. Management reports improvement in 11 of 12 sampled HEDIS and Patient Safety measures for the BY 2028 Star cycle and sees better inpatient trends for members in value based arrangements. Humana still carries a trailing twelve month net margin of 0.9%, below the prior year’s 1.3%, so the core earnings power is not yet rebuilt, but the operational milestones behind the bull story are beginning to show up in the numbers.

Access the full set of Humana forward scenarios, where the surface looks calm but the models start to disagree on revenue growth, medical cost ratios, and long term margin recovery inflection points with the street’s analyst estimates for Humana.

Humana Bear Case: Margin Repair Still An Unfinished Job

Bears argue Humana is too dependent on Medicare Advantage margins that are fragile and highly exposed to policy and cost shocks. The latest quarter does not clear that concern. Trailing twelve month net margin sits at 0.9%, below the prior 1.3%. That keeps the business firmly in margin repair mode rather than in a steady earnings phase.

Management talks about a path to at least 3% Medicare Advantage pretax margin in 2028 and expects meaningful progress in 2027. However, there is still no quantified 2027 margin guidance, which leaves a key bear milestone unmet. Cost trends for 2026 remain in the high single digits with pharmacy running higher, which lines up with worries about specialty cost pressure. Stars metrics are improving across sampled measures, yet the actual ratings and revenue impact will not be known until the blackout period ends.

After a year with thinner margins and large one off items, is Humana’s margin repair story masking deeper structural issues? Review the risk analysis for Humana which shows 2 important warning signs

Take Control Of Your Next Move

If Humana’s margin repair story has you watching for a better entry point or confirmation that the rebuild is on track, register for free with Simply Wall St and add it to a Watchlist to track share price against fair value and key fundamentals in one place. After you decide to take a position, keep your focus on what really matters with the Portfolio Command Center that pulls out the most important developments on your holdings and filters out day to day noise. For longer term conviction, tap into the crowd’s thinking through the Community and see how other investors are interpreting the same earnings, margins and risks. By spotting potential catalysts and red flags early, you give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Humana?

Fresh stock ideas can start breaking out while you are still focused on a single story. Spot momentum early, before the crowd catches on and information goes stale. Act now.

• Explore potential steadier income streams by focusing on curated yield opportunities inside the 8 dividend fortresses before prices fully reflect their payout strength.
• Track where real earnings momentum may be building and filter out cash burners with the curated set of 65 profitable AI stocks that aren't just burning cash while they are still under the radar for now.
• Target companies with cleaner balance sheets and fewer surprises by scanning the hand picked list of solid balance sheet and fundamentals stocks (46 results) while the most resilient options are not yet fully crowded.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.